CASIF (CASI Pharmaceuticals) Growth Rank: 1 (As of Aug. 03, 2026) — 75% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASIF CASI Pharmaceuticals Inc CASIF
29 GF Score
Price $0.13
GF Value $1.10
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Growth Rank?

CASI Pharmaceuticals CASIF 29 Growth Rank is 1 as of Aug. 03, 2026, which is 75% below its 10-year median of 4.00. GuruFocus rates CASIF with a GF Score™ of 29/100 and a GF Value™ of $1.10 (Possible Value Trap). The stock has 5 warning signs investors should review.

CASI Pharmaceuticals has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

CASI Pharmaceuticals Growth Rank Related Terms

CASIF vs DCOY, PKTX, BIXT: Growth Rank Comparison

For the Biotechnology subindustry, CASI Pharmaceuticals's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CASI Pharmaceuticals Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Growth Rank distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Growth Rank falls into.


CASIF
29GF Score
CASI Pharmaceuticals Inc CASIF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
CASI Pharmaceuticals (CASIF) has a Growth Rank of 1 as of Aug. 03, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on CASI Pharmaceuticals and its competitors. This is 75% below median its historical median of 4.00. Over the past decade, CASI Pharmaceuticals' Growth Rank has ranged from 1.00 to 9.00.
Is CASI Pharmaceuticals' Growth Rank too high?
CASI Pharmaceuticals' current Growth Rank of 1 is 75% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Growth Rank compare to DCOY and PKTX?
CASI Pharmaceuticals' Growth Rank of 1 can be compared against companies in the Biotechnology industry. Historically, CASI Pharmaceuticals' own Growth Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Growth Rank is 1, which is 75% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CASI Pharmaceuticals (CASIF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.10, compared to a current price of $0.13 — trading 88.3% below its estimated fair value. The current Growth Rank is 1, which is 75% below median its 10-year median of 4.00. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For CASI Pharmaceuticals (CASIF), the current Growth Rank is 1 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of $0.13 is trading 88.3% below its estimated GF Value™ of $1.10. GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CASIF:

  • Growth Rank: 1 (75% below median its 10-year median of 4.00)
  • GF Value™: $1.10 vs. price of $0.13 (88.3% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CASI Pharmaceuticals Business Description

Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score

Get the complete analysis for CASIF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$1.10
GF Value